https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-02-23 / J Clin Oncol 35, 2017 (suppl 7S; abstract 153)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-02-23 / J Clin Oncol 35, 2017 (suppl 7S; abstract 153)2017-02-23 11:47:542021-05-19 14:29:04Safety, efficacy, and immunogenicity of autologous tumor lysate-pulsed dendritic cell vaccination therapy after resection of stage IIA (T2N0, T3N0) esophageal cancer: A phase I trial.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-02-15 / Cytotherapy 2017 04;19(4):500-513
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-02-15 / Cytotherapy 2017 04;19(4):500-5132017-02-15 00:00:002019-02-15 08:53:07Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-02-02 / Int J Hyperthermia 2017 Feb;:1-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-02-02 / Int J Hyperthermia 2017 Feb;:1-92017-02-02 00:00:002019-02-15 08:39:29Short-course preoperative radiotherapy combined with chemotherapy, delayed surgery and local hyperthermia for rectal cancer: a phase II study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-02-02 / Int J Hyperthermia 2017 Jun;33(4):419-427
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-02-02 / Int J Hyperthermia 2017 Jun;33(4):419-4272017-02-02 00:00:002019-04-03 10:11:43Targeting therapy-resistant cancer stem cells by hyperthermia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-02-01 / J. Immunother. 2017 Feb/Mar;40(2):71-76
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-02-01 / J. Immunother. 2017 Feb/Mar;40(2):71-762017-02-01 00:00:002019-02-15 08:52:03A Dendritic Cell Vaccine Combined With Radiotherapy Activates the Specific Immune Response in Patients With Esophageal Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-02-01 / Ther Adv Med Oncol 2017 May;9(5):347-368
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-02-01 / Ther Adv Med Oncol 2017 May;9(5):347-3682017-02-01 00:00:002017-02-01 00:00:00History and current state of immunotherapy in glioma and brain metastasis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-01-27 / Crit. Rev. Oncol. Hematol. 2017 Mar;111:87-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-01-27 / Crit. Rev. Oncol. Hematol. 2017 Mar;111:87-932017-01-27 00:00:002019-02-15 08:51:20Immunotherapy for the treatment of multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-01-25 / J Clin Pharm Ther 2017 Apr;42(2):155-164
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-01-25 / J Clin Pharm Ther 2017 Apr;42(2):155-1642017-01-25 00:00:002017-01-25 00:00:00Chemoradiation combined with regional hyperthermia for advanced oesophageal cancer: a systematic review and meta-analysis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-01-24 / Oncotarget 2017 Jan;8(4):7157-7174
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-01-24 / Oncotarget 2017 Jan;8(4):7157-71742017-01-24 00:00:002019-02-15 08:36:13Targeting immune checkpoints in malignant glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-01-21 / J Neurooncol 2017 04;132(2):255-266
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-01-21 / J Neurooncol 2017 04;132(2):255-2662017-01-21 00:00:002021-11-15 20:06:08Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease
